AURA - NASDAQ
Aura Biosciences, Inc.
$6.88
-0.29%Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotAura Biosciences, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Declining FCF warrants attention. Investigate whether due to temporary factors or fundamental deterioration.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Aura Biosciences, Inc. Cash Flow Statement
AURA • NASDAQ
| Aura Biosciences, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||
-106.2M | -86.9M | -76.4M | -58.8M | -35.3M | -22.2M | -24.2M | |
1.1M | 1.2M | 1.3M | 1.2M | 831K | 831K | 509K | |
0.0 | 0.0 | 0.0 | 0.0 | 14K | 0.0 | 11K | |
14.3M | 11.7M | 8.8M | 6.4M | 2.3M | 736K | 507K | |
32K | -3.2M | -1.9M | -325K | 4K | -3K | 43K | |
6M | -2.6M | 4.4M | -3.1M | -315K | -3.7M | 2.5M | |
-84.7M | -79.8M | -63.8M | -54.6M | -32.4M | -24.3M | -20.7M | |
INVESTING ACTIVITIES | |||||||
-447K | -1.3M | -709K | -1.1M | -2.1M | -771K | -2.2M | |
(0.0) | (0.0) | (0.0) | (66.8K) | (0.0) | (0.0) | (0.0) | |
-84M | -59.1M | -233.7M | -119.8M | (0.0) | (0.0) | (0.0) | |
120M | 129.2M | 120.4M | 53M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | -66.8K | 0.0 | 0.0 | 0.0 | |
(35.6M) | (68.8M) | -114M | -67.9M | -2.1M | -771K | -2.2M | |
FINANCING ACTIVITIES | |||||||
77.2M | 1.6M | 3.2M | 8.5M | 78.7M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -34K | -37K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -13K | |
0.0 | 0.0 | 1.5M | 430K | 334K | 163K | 57K | |
77.2M | 1.6M | 97.3M | 95.6M | 166.3M | 10M | 39.7M | |
CASH FLOW SUMMARY | |||||||
-186K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
27.8M | -9.4M | -80.5M | -26.8M | 131.7M | -15.1M | 16.8M | |
32.5M | 41.9M | 122.4M | 149.2M | 17.5M | 32.5M | 15.7M | |
60.3M | 32.5M | 41.9M | 122.4M | 149.2M | 17.5M | 32.5M | |
-85.2M | -81.1M | -64.6M | -55.7M | -34.5M | -25.1M | -22.9M |
SEC Filings
AURA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | April 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | April 29, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 20, 2026 | June 11, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 30, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 13, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 13, 2025 | 2025 |
Related Guides
Continue your AURA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.